Stonepine Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-159,598
| Closed | -$8.57M | – | 22 |
|
|
2022
Q3 | $8.57M | Sell |
159,598
-1,093
| -0.7% | -$58.7K | 3.85% | 9 |
|
|
2022
Q2 | $8.94M | Buy |
160,691
+42,550
| +36% | +$2.37M | 4.16% | 10 |
|
|
2022
Q1 | $8.29M | Buy |
+118,141
| New | +$8.29M | 3.44% | 12 |
|
|
2021
Q1 | – | Sell |
-522,738
| Closed | -$32.4M | – | 32 |
|
|
2020
Q4 | $32.4M | Buy |
522,738
+7,373
| +1% | +$457K | 24.83% | 1 |
|
|
2020
Q3 | $30.6M | Buy |
515,365
+367,237
| +248% | +$21.8M | 31.88% | 1 |
|
|
2020
Q2 | $10.3M | Sell |
148,128
-109,825
| -43% | -$7.66M | 20.02% | 2 |
|
|
2020
Q1 | $11.7M | Buy |
+257,953
| New | +$11.7M | 12.38% | 1 |
|
|
2019
Q4 | – | Sell |
-48,034
| Closed | -$2.98M | – | 28 |
|
|
2019
Q3 | $2.98M | Sell |
48,034
-220,448
| -82% | -$13.7M | 2.9% | 14 |
|
|
2019
Q2 | $19.1M | Buy |
268,482
+28,032
| +12% | +$2M | 13.16% | 1 |
|
|
2019
Q1 | $18.9M | Buy |
+240,450
| New | +$18.9M | 10.85% | 3 |
|